Excell Research is a clinical research facility dedicated to improving the lives of patients through the advancement of safe and effective medication therapies.
Founded over 15 years ago, Excell Research partners with major pharmaceutical sponsors to conduct clinical research trials for new medications and treatments primarily in the areas of psychiatry; Alzheimer’s Disease and memory loss; women’s health; and other central nervous system conditions such as migraines and fibromyalgia.
1. Sponsor: Alto Neuroscience
Protocol Number: ALTO-100-201
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
2. Sponsor: DeNovo Biopharma LLC
Protocol Number: DB104-01
Protocol Number: SEP361-226
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
Protocol Number: NBI-98854-ATS3019 & NBI-1065844-CIAS2023
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Protocol Number: BHV4157-302
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Protocol Number: 3110-305-002 & M21-201
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Studies to Evaluate the Efficacy, Safety, Tolerability, of Ubrogepant or Atogepant in the Treatment of Migraines in Children and Adolescents (Ages 6-17)
Protocol Number: 20-AVP-786-306
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type
For those interested in becoming a volunteer, Excell Research has a variety of studies that are testing new or investigational medications at no cost to volunteers! Learn more about how new treatments may help with your symptoms.
Clinical trials create a new opportunity for patients to receive alternative or more varied treatment, and to get up close and personal treatment from healthcare professionals. Often, clinical trials provide financially viable treatment options that may not have otherwise been available. By participating in a clinical trial, you would be aiding health care officials in their efforts to advance medical knowledge and to find new and better treatment options for patients.
New Treatments For Longer and Better-Quality Lives
The primary goal of all clinical trials is to determine that the new treatment is both effective and safe for patients. A clinical trial may seek a cure or new methods to ease the lives of patients with chronic illnesses. Participating in a clinical trial allows you to receive the most cutting-edge treatment or procedures in the medical field, and to assist in helping other patients live longer and better-quality lives.
To ensure the safety of patients during clinical trials, Excell Research follows guidelines set by organizations such as the U.S. Food & Drug Administration and the Global International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices (ICH GCP).
According to requirements of the Medical Board of California, medical providers at Excell Research are providing information about the Open Payments Database. The Open Payments database is a federal tool used to search payments made by drug and device companies to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov. This database was created so that patients can be informed of any possible influence pharmaceutical companies may have on their physician. As a dedicated research facility, the entirety of Excell Research’s income is from pharmaceutical companies; however, medical providers are paid for their work by Excell Research and not directly by any pharmaceutical company.